Sitravatinib
Cat.No:IS4570 Solarbio
CAS:1123837-84-2
Storage:Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Protein Tyrosine Kinase/PTK >
SitravatinibCAS:1123837-84-2
Storage:Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
CAS | 1123837-84-2 |
Name | Sitravatinib |
Molecular Formula | C33H29F2N5O4S |
Molecular Weight | 629.68 |
Solubility | Soluble in DMSO ≥3mg/mL(Need ultrasonic) |
Purity | ≥98% |
Appearance | White to off-white Solid |
Storage | Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD28502181 |
SMILES | COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F |
InChIKey | WLAVZAAODLTUSW-UHFFFAOYSA-N |
InChI | InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42) |
PubChem CID | 25212148 |
Target Point | c-Kit;PDGFRβ;PDGFRα; c-Met;Axl |
Passage | Protein Tyrosine Kinase/RTK |
Background | Sitravatinib is a novel small-molecule inhibitor that targets multiple RTKs involved in regulating S180 sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl. |
Unit | Bottle |
Specification | 5mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.